Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
about
P1343
High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcomaPazopanib in sarcomas: expanding the PALETTECarcinogenic Parasite Secretes Growth Factor That Accelerates Wound Healing and Potentially Promotes NeoplasiaSynovial sarcoma: recent discoveries as a roadmap to new avenues for therapyHDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial SarcomaRole of fibroblast growth factor 8 (FGF8) in animal models of osteoarthritis.Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential.Heterogeneous in vitro effects of doxorubicin on gene expression in primary human liposarcoma culturesTherapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.New therapeutic targets in soft tissue sarcoma.Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach.Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumorsConsistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor.Molecular target therapy for synovial sarcoma.Neuronal differentiation of synovial sarcoma and its therapeutic application.Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patientsFGFR3 has tumor suppressor properties in cells with epithelial phenotype.Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcomaModeling synovial sarcoma metastasis in the mouse: PI3'-lipid signaling and inflammation.Fibroblast growth factor control of cartilage homeostasis.Expression of claudin7 is tightly associated with epithelial structures in synovial sarcomas and regulated by an Ets family transcription factor, ELF3.Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling.Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy.A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway.Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2.Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.Sarcomas of the head and neck in adult patients: current concepts and future perspectives.Ubiquitin ligase RNF146 coordinates bone dynamics and energy metabolism.FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation.Sorafenib is active on lung metastases from synovial sarcoma.High-efficiency production of bioactive recombinant human fibroblast growth factor 18 in Escherichia coli and its effects on hair follicle growth.Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma.The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.Impact of plasma fibrinogen levels in benign and malignant soft tissue tumors.RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
P2860
Q21132376-09332725-6CF4-40E5-9BA6-ACE3ACD0F43BQ26825050-CB48FF3D-A828-49BF-ADFF-F41491FC0DA0Q27317022-5CA54CDF-1028-45AB-A2AD-1577A914C7DBQ28087134-3D31F097-60BB-4CD7-A9F5-215207D57D5CQ28468451-4C4D5BF6-F09E-4B79-BB38-701FA54A7EEDQ30492900-AFAC21D0-E3E1-4B14-80CD-6D5317430CF2Q33278631-F9D3FE84-3DC6-4C6F-8E92-390930960BEDQ33380436-1988F7A2-A586-4168-92BF-49F6B5461BB8Q33696791-95CFE33F-84DD-4436-B0A1-FF8144AB6E60Q33890597-ACB70C52-B71F-472D-906D-569CCCAB6170Q34267924-E5F4A84E-6B2E-4744-99ED-AE9A0E80B5D8Q34406228-52F6C0C8-6A70-4AA0-B510-C5781BBBDE22Q35018901-E5978282-2871-4AB3-AB83-51DAAC5EE72BQ35035462-E8A0ED9F-6BAC-4A04-8989-9864D6581FFDQ35993334-71BC7AC4-EA7A-40FC-B351-060F69D33E2FQ36429636-449CD70E-CAE2-46EA-BC66-78EC572E22E5Q36803618-86E308B9-15B1-44D1-BC99-DF5B0D16CCE5Q37094042-1B2B6A67-0071-44B8-9BED-0FFD8A226FF2Q37113037-C467D57D-A13F-4A5F-95C7-3EB3E649CA39Q37379626-E3EE8F33-4E41-4E43-AD0F-DD58B053D742Q37500347-A134588D-16EC-49A3-814F-CBF4A8FEF5B0Q38051582-53875467-70F9-429C-8781-0719152A5FDBQ38308261-FC78EACB-2F42-4021-BDB8-2F3845EFFA81Q38567366-BE5F0B20-2C8D-4A53-8F5E-FD0AF8D5BBC7Q38868203-0E35CF74-B1A6-4649-B5F9-D3AF3F4F1AF9Q39005693-7952549B-6AB4-4727-AE4E-2A7D724DFB2FQ39233440-FF78DDCB-FBE2-4D62-94D7-F8F4E0FB21E9Q39391651-58101C04-13D1-4AD2-9914-9AF69A23EB65Q39458600-133176C7-FA31-4133-A244-CCF7F1BF8C0BQ39624408-D16E2292-EDBF-4CEB-BEC1-11379107DAD7Q40059961-50EF2A14-85AC-4012-AA79-580365549988Q41661724-9CADCB68-42A1-4DCC-BFB5-589BADD2B3FCQ45370913-D9FB1820-83DD-40AE-9607-3FAFC0F81E7EQ46124730-1B27E86A-C528-47D1-83B0-806066EE5E74Q48039657-223F90CD-C3ED-49B4-A014-8B8ED138D0D1Q50129409-6CD46C17-558E-4520-9AFD-590EA550885FQ50420957-273C3B81-4E1E-4DBC-86B7-DEE6A27DB7A5Q53125747-CAA1B549-8D98-4236-AC02-C0A2DD7A7ED1Q53478339-82D2AAFD-58B6-42DE-8D9E-98DF79D48C8A
P2860
Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Disruption of fibroblast growt ...... s to molecular target therapy.
@en
type
label
Disruption of fibroblast growt ...... s to molecular target therapy.
@en
prefLabel
Disruption of fibroblast growt ...... s to molecular target therapy.
@en
P2093
P1476
Disruption of fibroblast growt ...... s to molecular target therapy.
@en
P2093
Junya Toguchida
Koichi Nishijo
Kotaro Roberts Shibata
Satoshi Nagayama
Takashi Nakamura
Takeshi Okamoto
Tatsuya Ishibe
Tomitaka Nakayama
Tomoki Aoyama
Toyomasa Katagiri
P304
P356
10.1158/1078-0432.CCR-04-2057
P407
P4510
P577
2005-04-01T00:00:00Z